BBC3/PUMA is a critical apoptosis inducer whose expression ablation is oncogenic and can lead to therapeutic resistance.39 A recent study demonstrated that BBC3/PUMA is the critical determinant of the therapeutic response to p53 activation and subsequent apoptosis induced by Nutlin3a, a cancer therapeutics that is in clinical trial.40 A screening study with flubendazole, another compound that exerts anti‐cancer activity, identified neuroblastoma as a potential flubendazole‐sensitive cancer entity. This evidence concerns the gene TP53 and cancer.